Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus.
In the present study, we evaluated the anti-seizure and anti-myoclonic activity of levetiracetam and brivaracetam in an established rat model of cardiac arrest-induced post-hypoxic myoclonus. We found that brivaracetam (0.3 mg/kg, the minimal effective dose) was more potent than levetiracetam (3 mg/kg, the minimal effective dose) against post-hypoxic seizures. The anti-seizure activity of both compounds occurred 30 min following intraperitoneal (i.p.) administration and was maintained over the entire 150 min post-dose observation period. Both brivaracetam and levetiracetam significantly reduced auditory stimulated post-hypoxic myoclonus from a dose 0.3 mg/kg. At that dose, the anti-myoclonic activity of brivaracetam was already maximal whereas it continued to increase in a dose-relation manner with levetiracetam, suggesting that brivaracetam is a more potent agent. The onset and the duration of anti-myoclonic activity of both compounds were similar. These findings demonstrate that brivaracetam possesses more potent anti-seizure and anti-myoclonic activity than levetiracetam in an established rat model of cardiac arrest-induced post-hypoxic myoclonus.
Tai
K-K
KK
Long Beach Memorial Medical Center, The Parkinson's and Movement Disorder Research Laboratory, Long Beach, California 90806, USA. kktai@yahoo.com
Truong
D D
DD
D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004831:Epilepsies, Myoclonic / Q000188:drug therapy* / Q000209:etiology; D006323:Heart Arrest / Q000150:complications; D000860:Hypoxia / Q000209:etiology; D000077287:Levetiracetam; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011760:Pyrrolidinones / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000188:drug therapy / Q000209:etiology
D000927:Anticonvulsants; D011760:Pyrrolidinones; D000077287:Levetiracetam; C482793:brivaracetam; D010889:Piracetam
J Cereb Blood Flow Metab. 1995 Mar;15(2):248-58
7860659
Seizure. 2006 Apr;15(3):214-8
16420982
Arch Neurol. 1975 May;32(5):304-7
806277
Neurology. 2001 Feb 13;56(3):411-2
11171914
N Engl J Med. 1978 Aug 10;299(6):313-4
351404
Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8
16556440
Adv Neurol. 1986;43:157-69
3080849
Brain Res. 2005 Oct 19;1059(2):122-8
16197930
J Med Chem. 2004 Jan 29;47(3):530-49
14736235
Mov Disord. 2000;15 Suppl 1:26-30
10755269
Neurology. 2004 May 25;62(10 ):1879-81
15159501
Epileptic Disord. 2000 Dec;2(4):209-12
11174151
Epilepsia. 2001;42 Suppl 4:13-8
11564119
Epilepsy Res. 1998 Jan;29(2):147-54
9477147
Seizure. 2003 Dec;12(8):617-20
14630506
Epilepsy Res. 2006 Sep;71(1):32-9
16814521
Epilepsy Res. 2006 Jun;69(3):273-94
16621450
Neurosci Lett. 2001 Jun 22;306(1-2):5-8
11403944
Adv Neurol. 1979;26:49-84
229719
Adv Neurol. 2002;89:295-306
11968456
Curr Opin Investig Drugs. 2005 Jul;6(7):740-6
16044671
Br J Pharmacol. 2002 Jul;136(5):659-72
12086975
Epilepsia. 2002 Jan;43(1):9-18
11879381
Mov Disord. 1994 Mar;9(2):201-6
8196684
Mov Disord. 2000;15 Suppl 1:31-8
10755270
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
15210974
Clin Neurosci. 1995-1996;3(4):236-45
8891397